# Trump Reclassifies State-Licensed Medical Cannabis, but It's Not Legal Just Yet
The Trump administration has reclassified state-licensed medical cannabis, marking a shift in federal policy toward cannabis regulation. However, the change stops short of full legalization and leaves significant questions about how the drug will be prescribed, researched, and accessed across the country.
The reclassification acknowledges that cannabis has medical applications in states where it's already legal. This represents a change from its previous classification as a Schedule I controlled substance with no accepted medical use. Supporters argue the move could open pathways for more medical research and clearer guidelines for patients in states with medical cannabis programs.
But the new status doesn't mean federal legalization. Parents should understand that cannabis remains illegal at the federal level. The reclassification creates a middle ground that permits state programs to operate without certain federal restrictions, yet federal law still generally prohibits possession and distribution.
For families, this matters if a child has a qualifying condition in a state with medical cannabis programs. The reclassification could simplify access through state-licensed dispensaries and may encourage researchers to study cannabis safety and efficacy more thoroughly. However, insurance rarely covers medical cannabis, and prescribing guidelines remain unclear.
The American Academy of Pediatrics maintains that cannabis use in developing brains carries risks. Research from institutions like the University of Colorado and Johns Hopkins shows THC exposure during childhood and adolescence can affect memory, attention, and academic performance. These concerns don't disappear with reclassification.
Parents in states with medical programs should consult pediatricians and pediatric specialists about whether cannabis makes sense for their child's condition. State licensing requirements vary considerably. Some states require strict age verification and dosing protocols, while others have looser oversight.
The reclassification opens doors for research that could answer outstanding questions about safety, dosing, and long